JP2017536826A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536826A5 JP2017536826A5 JP2017527898A JP2017527898A JP2017536826A5 JP 2017536826 A5 JP2017536826 A5 JP 2017536826A5 JP 2017527898 A JP2017527898 A JP 2017527898A JP 2017527898 A JP2017527898 A JP 2017527898A JP 2017536826 A5 JP2017536826 A5 JP 2017536826A5
- Authority
- JP
- Japan
- Prior art keywords
- population
- cells
- sh2b3
- stem cells
- rbc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 claims description 84
- 210000003743 erythrocyte Anatomy 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 39
- 101000616523 Homo sapiens SH2B adapter protein 3 Proteins 0.000 claims description 38
- 102100021778 SH2B adapter protein 3 Human genes 0.000 claims description 33
- 239000005557 antagonist Substances 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 238000010362 genome editing Methods 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 102000014400 SH2 domains Human genes 0.000 claims description 4
- 108050003452 SH2 domains Proteins 0.000 claims description 4
- 238000010459 TALEN Methods 0.000 claims description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 108091030071 RNAI Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000000816 peptidomimetic Substances 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000004952 protein activity Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000003954 umbilical cord Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462083439P | 2014-11-24 | 2014-11-24 | |
| US62/083,439 | 2014-11-24 | ||
| PCT/US2015/062333 WO2016085934A1 (en) | 2014-11-24 | 2015-11-24 | Modulation of sh2b3 to improve red blood cell production from stem cells and/or progenitor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536826A JP2017536826A (ja) | 2017-12-14 |
| JP2017536826A5 true JP2017536826A5 (enExample) | 2019-01-10 |
Family
ID=56074950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527898A Pending JP2017536826A (ja) | 2014-11-24 | 2015-11-24 | 幹細胞および／または前駆細胞からの赤血球産生を改善するためのｓｈ２ｂ３の調節 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170355958A1 (enExample) |
| EP (1) | EP3224350A4 (enExample) |
| JP (1) | JP2017536826A (enExample) |
| CN (1) | CN107429231A (enExample) |
| WO (1) | WO2016085934A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107663515B (zh) * | 2016-07-28 | 2020-12-15 | 苏州方舟生物医药有限公司 | 一种定向制备人红细胞的方法及制剂 |
| DE102017107661A1 (de) * | 2017-04-10 | 2018-10-11 | Universität Rostock | SH2B-Adapterprotein-3 für die Vorhersage einer Knochenmarkantwort und Immunantwort |
| WO2019084531A1 (en) | 2017-10-27 | 2019-05-02 | The Children's Hospital Of Philadelphia | MODIFIED RED GLOBES HAVING PHENOTYPES OF RARE ANTIGENS |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| DE102018125324A1 (de) * | 2018-10-12 | 2020-04-16 | Universität Rostock | Verfahren zur Vorhersage einer Antwort auf die Therapie von Krankheiten |
| WO2020174472A1 (en) | 2019-02-26 | 2020-09-03 | Rambam Med-Tech Ltd. | Cells and methods for improved immunotherapy |
| US20230212513A1 (en) * | 2020-06-19 | 2023-07-06 | The Children's Medical Center Corporation | Compositions and methods for red blood cell differentiation |
| CN112143697B (zh) * | 2020-10-08 | 2021-08-06 | 宁波希诺赛生物科技有限公司 | 一种促进胚胎干细胞增殖和分化的方法 |
| CN113025579A (zh) * | 2021-04-22 | 2021-06-25 | 河南农业大学 | 一种稳定敲低猪abhd16a基因的ST-KDABHD16A细胞系及其构建方法 |
| CN116640728B (zh) * | 2023-07-24 | 2023-10-20 | 呈诺再生医学科技(北京)有限公司 | RO8191和AS2863619在诱导产生表达成人型β珠蛋白的脱核红细胞中的应用 |
| CN119535779B (zh) * | 2025-01-23 | 2025-05-06 | 浙江农林大学 | 空间频域成像中结构光漫反射图案仿真模型的构建方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011071085A1 (ja) * | 2009-12-08 | 2011-06-16 | 国立大学法人東京大学 | 多能性幹細胞から分化誘導された細胞の生産方法 |
| US20140328811A1 (en) * | 2011-08-01 | 2014-11-06 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
| PL2890780T3 (pl) * | 2012-08-29 | 2021-02-08 | Sangamo Therapeutics, Inc. | Sposoby i kompozycje do leczenia zaburzeń genetycznych |
-
2015
- 2015-11-24 CN CN201580074325.7A patent/CN107429231A/zh not_active Withdrawn
- 2015-11-24 EP EP15863890.8A patent/EP3224350A4/en not_active Withdrawn
- 2015-11-24 US US15/529,220 patent/US20170355958A1/en not_active Abandoned
- 2015-11-24 WO PCT/US2015/062333 patent/WO2016085934A1/en not_active Ceased
- 2015-11-24 JP JP2017527898A patent/JP2017536826A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536826A5 (enExample) | ||
| AU2022206811B2 (en) | Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids | |
| US20230285538A1 (en) | Efficacious mrna vaccines | |
| Hur et al. | CD82/KAI1 maintains the dormancy of long-term hematopoietic stem cells through interaction with DARC-expressing macrophages | |
| JP7706785B2 (ja) | 腎臓病治療のための免疫特権を有する生物活性腎細胞 | |
| CN102626517B (zh) | 调节造血干细胞生长的方法 | |
| Mao et al. | MicroRNA-23a is involved in tumor necrosis factor-α induced apoptosis in mesenchymal stem cells and myocardial infarction | |
| JP5840119B2 (ja) | 誘導多能性幹細胞の製造方法 | |
| EP3612623A1 (en) | Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure | |
| WO2014118817A2 (en) | Platelets transfected by exogenous genetic material and platelet microparticles obtained by said transfected platelets, method for the preparation and uses thereof | |
| Kowalski et al. | Stromal derived factor‐1 and granulocyte‐colony stimulating factor treatment improves regeneration of Pax7−/− mice skeletal muscles | |
| US20240390425A1 (en) | Rejuvenated aged hematopoietic stem cells and methods of use | |
| Zuo et al. | Study on the interactions between transplanted bone marrow-derived mesenchymal stem cells and regulatory T cells for the treatment of experimental colitis | |
| JPWO2011090068A1 (ja) | 癌組織由来細胞塊または癌細胞凝集塊の培養方法、評価方法および保存方法 | |
| CN108135941B (zh) | 用于治疗移植物抗宿主病的组合物和方法 | |
| WO2016011381A1 (en) | Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells | |
| JP6861405B2 (ja) | 造血系細胞の作製方法 | |
| US20190000885A1 (en) | Treatment with angiogenin to enhance hematopoietic reconstitution | |
| Yoder | Early and late endothelial progenitor cells are miR-tually exclusive | |
| Li et al. | Enhanced interaction between genome-edited mesenchymal stem cells and platelets improves wound healing in mice | |
| KR20250121325A (ko) | T 세포 조작을 개선하기 위한 인슐린 치료 | |
| CN117500513A (zh) | 用于范可尼贫血的与巨核细胞来源的细胞外囊泡相关的组合物和方法 | |
| Chen et al. | Sca‐1+ mesenchymal stromal cells inhibit splenic marginal zone B lymphocytes commitment through Caspase‐3 | |
| Fath-Bayati et al. | Tracking of intraperitoneally and direct intrahepatic administered mesenchymal stem cells expressing miR-146a-5p in mice hepatic tissue | |
| Selich et al. | IFN‐γ‐Induced CD317 Tethers Extracellular Vesicles to Mesenchymal Stromal Cells Interfering With Immune Modulation |